

HLS Therapeutics Inc.

HLS Therapeutics to Host Q1 2020 Financial Results Conference Call

TORONTO, April 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 7, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer. **To participate on the call, please enter a dial-in number below and then enter the Conference ID when prompted.**

CONFERENCE ID: 6457646

DATE: Thursday, May 7, 2020

TIME: 8:30 a.m. Eastern Time

DIAL-IN NUMBER: 1-877-267-7318 or 631-485-5848

WEBCAST LINK: https://produceredition.webcasts.com/starthere.jspei=1311902&tp_key=59c36737e9

TAPED REPLAY: 1-855-859-2056 or 404-537-3406

REPLAY CODE: 6457646

The taped replay will be available for 14 days and the archived webcast will be available for 90 days.

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

For further information: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, dave.mason@loderockadvisors.com; Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, g.godin@hlstherapeutics.com

<https://hlstherapeutics.investorroom.com/2020-04-30-HLS-Therapeutics-to-Host-Q1-2020-Financial-Results-Conference-Call>